An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
An Open-label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox in Subjects With Impaired Renal Function and Healthy Volunteers
Sponsor: ApoPharma
A PHASE4 clinical study on Renal Impairment, this trial is completed. The trial is conducted by ApoPharma and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ApoPharma
For direct contact, visit the study record on ClinicalTrials.gov .